Pruritus News and Research

RSS

Researchers review the epidemiology, clinical character, treatment, and prevention of human monkeypox

Researchers reviewed the epidemiology, clinical character, treatment, and prevention of human monkeypox.

8 Sep 2022

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with historical controls despite a shortened interval (6 months) of treatment.

8 Aug 2022

COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis

In a recent study published in the Journal of Hepatology, researchers reported that the coronavirus disease 2019 (COVID-19) vaccination could elicit a distinct T cell-dominant immune-mediated hepatitis.

25 Apr 2022

FDA approves an intravenous medication to treat patients with Pompe disease

Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.

6 Aug 2021

Next-Generation Sequencing and the Diagnosis of Disease

In this interview, Professor John Rossen talks about next-generation sequencing and it's implications for the diagnosis of disease.

From Tecan 4 Aug 2021

FDA approves Stratagraft for thermal burn treatment in adult patients

Today, the U.S. Food and Drug Administration approved StrataGraft for the treatment of adult patients with thermal burns containing intact dermal elements (remaining deep skin layers) for which surgical intervention is clinically indicated (also referred to as deep partial thickness burns).

15 Jun 2021

FDA issues EUA for bamlanivimab and etesevimab for COVID-19 treatment

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.

10 Feb 2021

Symptom under-recognition may be common in breast cancer patients treated with radiotherapy

Among patients with breast cancer treated with radiotherapy, under-recognition of symptoms was common in reports of pain, pruritus, edema, and fatigue, with younger patients and Black patients having significantly increased odds of symptom under-recognition, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.

9 Dec 2020

Mallinckrodt publishes results of StrataGraft regenerative tissue Phase 1b study

Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.

16 Aug 2019

Racial and ethnic disparities exist in palliative care use among hospitalized patients with ESKD

Striking racial and ethnic disparities exist in the use of palliative care by hospitalized patients with end-stage kidney disease on dialysis, researchers at the Icahn School of Medicine at Mount Sinai report. The findings were published today in Journal of the American Society of Nephrology.

8 Aug 2019

Study explains why some drugs work well in ameliorating side effects of chemotherapy

Researchers at the University of Zurich have determined the three-dimensional structure of the receptor that causes nausea and vomiting as a result of cancer chemotherapy.

10 Jan 2019

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1

International collaborative research led by Ludwine Messiaen, Ph.D., shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis type 1, or NF1, the mutation does cause complications.

18 Sep 2018

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved AJOVY injection for the preventive treatment of migraine in adults.

17 Sep 2018

Pruritus News and Research

Researchers review the epidemiology, clinical character, treatment, and prevention of human monkeypox

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis

FDA approves an intravenous medication to treat patients with Pompe disease

Next-Generation Sequencing and the Diagnosis of Disease

FDA approves Stratagraft for thermal burn treatment in adult patients

FDA issues EUA for bamlanivimab and etesevimab for COVID-19 treatment

Symptom under-recognition may be common in breast cancer patients treated with radiotherapy

Mallinckrodt publishes results of StrataGraft regenerative tissue Phase 1b study

Racial and ethnic disparities exist in palliative care use among hospitalized patients with ESKD

Study explains why some drugs work well in ameliorating side effects of chemotherapy

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Realizing the Importance of Medical Electronic Devices

Everything about SpatialOMx

How the science of happiness is helping student mental health

Latest News

Drug Discovery eBook